Alto Neuroscience, Inc. (NYSE:ANRO) Receives $8.50 Average PT from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.50.

Several analysts have recently weighed in on ANRO shares. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Alto Neuroscience in a research report on Monday, August 18th. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Alto Neuroscience in a research report on Thursday, May 15th.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently modified their holdings of ANRO. Bank of Montreal Can purchased a new stake in shares of Alto Neuroscience during the 2nd quarter worth approximately $25,000. Ground Swell Capital LLC purchased a new stake in Alto Neuroscience in the 2nd quarter valued at $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Alto Neuroscience in the 2nd quarter valued at $33,000. AlphaCore Capital LLC raised its position in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the last quarter.

Alto Neuroscience Stock Up 8.8%

Shares of Alto Neuroscience stock opened at $3.9070 on Monday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $15.04. The company has a 50 day moving average of $2.80 and a 200 day moving average of $2.72. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $105.80 million, a P/E ratio of -1.63 and a beta of 1.84.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). As a group, research analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.